Ran Zheng

Ran is an accomplished biotech leader with deep expertise in business strategy, therapeutic development, and technical operations across established biopharma and cutting-edge startups. Most recently, Ran served as CEO of Landmark Bio, an innovative biomanufacturing company for advanced therapies she built from the ground up. Previously, Ran served as Chief Technical Officer at Orchard Therapeutics, where she played a key role in advancing the product pipeline and securing the European approval of Libmeldy® - the first gene therapy product for metachromatic leukodystrophy (MLD) in the region. Earlier in her career, Ran held various leadership positions with increasing responsibilities at several major biotechnology companies including Genzyme (now part of Sanofi) and Amgen, where she contributed to the development and commercialization of multiple groundbreaking medicines.